FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2040603581> ?p ?o ?g. }

• W2040603581 endingPage "100S" @default.
• W2040603581 startingPage "92S" @default.
• W2040603581 abstract "Progress in the treatment of patients with small cell lung cancer (SCLC) has come in two phases. In the first phase, SCLC was recognized, even when seemingly localized to the lung and intrathoracic lymph nodes, to be widely metastatic and to require effective systemic therapy from the outset. The development of active chemotherapeutic agents and combinations in the 1970s improved median survival from the 6 months seen with radiotherapy alone to about 1 year. In the second phase has come the recognition that local control of a disease, even one with systemic spread, is necessary for its cure. This has resulted both in a better appreciation of the role of radiation therapy in SCLC treatment and in efforts to optimize combined-modality regimens using radiotherapy and chemotherapy. With current treatment regimens involving concurrent or closely interdigitated administration of cisplatin and etoposide chemotherapy and radiation doses of 45 Gy given over 3 to 5 weeks, median survivals of 20 to 24 months have been reported by many single institutions and confirmed in large cooperative group trials. Issues remaining to be resolved include optimization of radiation dose, volume, and timing; the role of prophylactic cranial irradiation; and how to reduce acute and late toxic reactions of treatment. As we develop more specific therapies based on specific molecular and biological characteristics of SCLC, including its autocrine growth regulation, we will be challenged to integrate these successfully with current radiation and chemotherapeutic approaches. Progress in the treatment of patients with small cell lung cancer (SCLC) has come in two phases. In the first phase, SCLC was recognized, even when seemingly localized to the lung and intrathoracic lymph nodes, to be widely metastatic and to require effective systemic therapy from the outset. The development of active chemotherapeutic agents and combinations in the 1970s improved median survival from the 6 months seen with radiotherapy alone to about 1 year. In the second phase has come the recognition that local control of a disease, even one with systemic spread, is necessary for its cure. This has resulted both in a better appreciation of the role of radiation therapy in SCLC treatment and in efforts to optimize combined-modality regimens using radiotherapy and chemotherapy. With current treatment regimens involving concurrent or closely interdigitated administration of cisplatin and etoposide chemotherapy and radiation doses of 45 Gy given over 3 to 5 weeks, median survivals of 20 to 24 months have been reported by many single institutions and confirmed in large cooperative group trials. Issues remaining to be resolved include optimization of radiation dose, volume, and timing; the role of prophylactic cranial irradiation; and how to reduce acute and late toxic reactions of treatment. As we develop more specific therapies based on specific molecular and biological characteristics of SCLC, including its autocrine growth regulation, we will be challenged to integrate these successfully with current radiation and chemotherapeutic approaches." @default.
• W2040603581 created "2016-06-24" @default.
• W2040603581 creator A5079283183 @default.
• W2040603581 date "1998-01-01" @default.
• W2040603581 modified "2023-09-26" @default.
• W2040603581 title "Radiation Therapy in the Management of Limited Small Cell Lung Cancer" @default.
• W2040603581 cites W1885320430 @default.
• W2040603581 cites W1905406155 @default.
• W2040603581 cites W1938763320 @default.
• W2040603581 cites W1945129735 @default.
• W2040603581 cites W1951176292 @default.
• W2040603581 cites W1973865448 @default.
• W2040603581 cites W1974262012 @default.
• W2040603581 cites W1976276185 @default.
• W2040603581 cites W1983328140 @default.
• W2040603581 cites W1987149868 @default.
• W2040603581 cites W1989315499 @default.
• W2040603581 cites W2001739398 @default.
• W2040603581 cites W2028034931 @default.
• W2040603581 cites W2052646463 @default.
• W2040603581 cites W2065595116 @default.
• W2040603581 cites W2070645346 @default.
• W2040603581 cites W2077233371 @default.
• W2040603581 cites W2088766047 @default.
• W2040603581 cites W2089016789 @default.
• W2040603581 cites W2120421794 @default.
• W2040603581 cites W2121307626 @default.
• W2040603581 cites W2121624379 @default.
• W2040603581 cites W2127947104 @default.
• W2040603581 cites W2149195901 @default.
• W2040603581 cites W2158034304 @default.
• W2040603581 cites W2158628168 @default.
• W2040603581 cites W2164306710 @default.
• W2040603581 cites W2182914054 @default.
• W2040603581 cites W2235132496 @default.
• W2040603581 cites W2243683089 @default.
• W2040603581 cites W2258518953 @default.
• W2040603581 cites W2314635417 @default.
• W2040603581 cites W2341745217 @default.
• W2040603581 doi "https://doi.org/10.1378/chest.113.1_supplement.92s" @default.
• W2040603581 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9438697" @default.
• W2040603581 hasPublicationYear "1998" @default.
• W2040603581 type Work @default.
• W2040603581 sameAs 2040603581 @default.
• W2040603581 citedByCount "7" @default.
• W2040603581 countsByYear W20406035812012 @default.
• W2040603581 countsByYear W20406035812016 @default.
• W2040603581 crossrefType "journal-article" @default.
• W2040603581 hasAuthorship W2040603581A5079283183 @default.
• W2040603581 hasConcept C126322002 @default.
• W2040603581 hasConcept C143998085 @default.
• W2040603581 hasConcept C2776256026 @default.
• W2040603581 hasConcept C2776694085 @default.
• W2040603581 hasConcept C2778119113 @default.
• W2040603581 hasConcept C2779562246 @default.
• W2040603581 hasConcept C45393284 @default.
• W2040603581 hasConcept C500558357 @default.
• W2040603581 hasConcept C509974204 @default.
• W2040603581 hasConcept C71924100 @default.
• W2040603581 hasConceptScore W2040603581C126322002 @default.
• W2040603581 hasConceptScore W2040603581C143998085 @default.
• W2040603581 hasConceptScore W2040603581C2776256026 @default.
• W2040603581 hasConceptScore W2040603581C2776694085 @default.
• W2040603581 hasConceptScore W2040603581C2778119113 @default.
• W2040603581 hasConceptScore W2040603581C2779562246 @default.
• W2040603581 hasConceptScore W2040603581C45393284 @default.
• W2040603581 hasConceptScore W2040603581C500558357 @default.
• W2040603581 hasConceptScore W2040603581C509974204 @default.
• W2040603581 hasConceptScore W2040603581C71924100 @default.
• W2040603581 hasIssue "1" @default.
• W2040603581 hasLocation W20406035811 @default.
• W2040603581 hasLocation W20406035812 @default.
• W2040603581 hasOpenAccess W2040603581 @default.
• W2040603581 hasPrimaryLocation W20406035811 @default.
• W2040603581 hasRelatedWork W2015473806 @default.
• W2040603581 hasRelatedWork W2029688276 @default.
• W2040603581 hasRelatedWork W2067245977 @default.
• W2040603581 hasRelatedWork W2082691227 @default.
• W2040603581 hasRelatedWork W2348495938 @default.
• W2040603581 hasRelatedWork W2357406576 @default.
• W2040603581 hasRelatedWork W2389384568 @default.
• W2040603581 hasRelatedWork W2419189404 @default.
• W2040603581 hasRelatedWork W4382279650 @default.
• W2040603581 hasRelatedWork W1899415052 @default.
• W2040603581 hasVolume "113" @default.
• W2040603581 isParatext "false" @default.
• W2040603581 isRetracted "false" @default.
• W2040603581 magId "2040603581" @default.
• W2040603581 workType "article" @default.